HIV vaccine - Profectus Biosciences

Drug Profile

HIV vaccine - Profectus Biosciences

Alternative Names: HIV-1 vaccine - Profectus Biosciences; HIV-1-gag-vaccine; Recombinant vesicular stomatitis virus HIV-1 gag vaccine; rVSV HIV vaccine - Profectus Biosciences; rVSV HIV-1 gag vaccine; rVSVIN HIV-1 gag vaccine; rVSVN4CT1 HIV

Latest Information Update: 04 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 31 Oct 2014 Profectus in-licenses vaccine delivery technology from Yale University prior to October 2014
  • 17 Sep 2013 Phase-I clinical trials in HIV infections in USA (IM)
  • 04 Dec 2012 Final adverse events and immunogenicity data from a phase I trial in HIV infection (prevention) released by Profectus Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top